Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss

Mark D Stegall, Gregory T. Everson, Gerhard Schroter, Frederick Karrer, Bahri Bilir, Tracy Sternberg, Roshan Shrestha, Michael Wachs, Igal Kam

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

We prospectively withdrew prednisone in 28 adult patients who had stable graft function more than 2 years after orthotopic liver transplantation (OLTx) and had been on 5 mg/d prednisone for at least 6 months. Prednisone was decreased from 5 mg/d to 2.5 mg/d for 1 month then stopped completely. Cyclosporine monotherapy was maintained at a level of approximately 200 ng/mL (TDX). Nineteen patients had prednisone withdrawn without complications. Four (14.2%) had modest elevations in liver function tests (two biopsy proven mild rejections and two were not biopsied). These four were treated with methylprednisolone boluses and then withdrawal of steroids again. Prednisone was restarted in five patients because of generalized fatigue and body aches (n = 4) and colitis (n = 1). Steroids later were successfully withdrawn in two of these patients. After prednisone withdrawal, three of five insulin- dependent diabetic patients were able to discontinue insulin therapy and their glycosylated hemoglobin levels improved. Four of fourteen hypertensive patients were able to discontinue antihypertensive medicines. Mean serum cholesterol decreased from 222.6 ± 43.3 to 188.3 ± 33.3 mg/dL (P < .001). The number of patients with serum cholesterol levels > 220 mg/dL decreased from 13 to 4. A control group of 24 patients maintained on 5 mg/d prednisone at least 2 years after liver transplantation also was studied. In this group during the study period, no diabetic became normoglycemic, no patient decreased their anti-hypertensive medicine, and the mean serum cholesterol levels did not change significantly. We conclude that prednisone withdrawal using cyclosporine monotherapy late after liver transplantation does not lead to graft loss and decreases the prevalence of diabetes, hypertension, and hypercholesterolemia. Symptoms occurring during withdrawal may be minimized by earlier or slower tapering.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalHepatology
Volume25
Issue number1
StatePublished - Jan 1997
Externally publishedYes

Fingerprint

Prednisone
Hypercholesterolemia
Liver Transplantation
Hypertension
Transplants
Antihypertensive Agents
Cyclosporine
Steroids
Cholesterol
Insulin
Liver Function Tests
Methylprednisolone
Glycosylated Hemoglobin A
Colitis
Serum
Fatigue
Medicine
Biopsy
Pain
Control Groups

ASJC Scopus subject areas

  • Hepatology

Cite this

Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. / Stegall, Mark D; Everson, Gregory T.; Schroter, Gerhard; Karrer, Frederick; Bilir, Bahri; Sternberg, Tracy; Shrestha, Roshan; Wachs, Michael; Kam, Igal.

In: Hepatology, Vol. 25, No. 1, 01.1997, p. 173-177.

Research output: Contribution to journalArticle

Stegall, MD, Everson, GT, Schroter, G, Karrer, F, Bilir, B, Sternberg, T, Shrestha, R, Wachs, M & Kam, I 1997, 'Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss', Hepatology, vol. 25, no. 1, pp. 173-177.
Stegall, Mark D ; Everson, Gregory T. ; Schroter, Gerhard ; Karrer, Frederick ; Bilir, Bahri ; Sternberg, Tracy ; Shrestha, Roshan ; Wachs, Michael ; Kam, Igal. / Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. In: Hepatology. 1997 ; Vol. 25, No. 1. pp. 173-177.
@article{e31f0d2b4f2c4119a6bc6473a555c8d2,
title = "Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss",
abstract = "We prospectively withdrew prednisone in 28 adult patients who had stable graft function more than 2 years after orthotopic liver transplantation (OLTx) and had been on 5 mg/d prednisone for at least 6 months. Prednisone was decreased from 5 mg/d to 2.5 mg/d for 1 month then stopped completely. Cyclosporine monotherapy was maintained at a level of approximately 200 ng/mL (TDX). Nineteen patients had prednisone withdrawn without complications. Four (14.2{\%}) had modest elevations in liver function tests (two biopsy proven mild rejections and two were not biopsied). These four were treated with methylprednisolone boluses and then withdrawal of steroids again. Prednisone was restarted in five patients because of generalized fatigue and body aches (n = 4) and colitis (n = 1). Steroids later were successfully withdrawn in two of these patients. After prednisone withdrawal, three of five insulin- dependent diabetic patients were able to discontinue insulin therapy and their glycosylated hemoglobin levels improved. Four of fourteen hypertensive patients were able to discontinue antihypertensive medicines. Mean serum cholesterol decreased from 222.6 ± 43.3 to 188.3 ± 33.3 mg/dL (P < .001). The number of patients with serum cholesterol levels > 220 mg/dL decreased from 13 to 4. A control group of 24 patients maintained on 5 mg/d prednisone at least 2 years after liver transplantation also was studied. In this group during the study period, no diabetic became normoglycemic, no patient decreased their anti-hypertensive medicine, and the mean serum cholesterol levels did not change significantly. We conclude that prednisone withdrawal using cyclosporine monotherapy late after liver transplantation does not lead to graft loss and decreases the prevalence of diabetes, hypertension, and hypercholesterolemia. Symptoms occurring during withdrawal may be minimized by earlier or slower tapering.",
author = "Stegall, {Mark D} and Everson, {Gregory T.} and Gerhard Schroter and Frederick Karrer and Bahri Bilir and Tracy Sternberg and Roshan Shrestha and Michael Wachs and Igal Kam",
year = "1997",
month = "1",
language = "English (US)",
volume = "25",
pages = "173--177",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss

AU - Stegall, Mark D

AU - Everson, Gregory T.

AU - Schroter, Gerhard

AU - Karrer, Frederick

AU - Bilir, Bahri

AU - Sternberg, Tracy

AU - Shrestha, Roshan

AU - Wachs, Michael

AU - Kam, Igal

PY - 1997/1

Y1 - 1997/1

N2 - We prospectively withdrew prednisone in 28 adult patients who had stable graft function more than 2 years after orthotopic liver transplantation (OLTx) and had been on 5 mg/d prednisone for at least 6 months. Prednisone was decreased from 5 mg/d to 2.5 mg/d for 1 month then stopped completely. Cyclosporine monotherapy was maintained at a level of approximately 200 ng/mL (TDX). Nineteen patients had prednisone withdrawn without complications. Four (14.2%) had modest elevations in liver function tests (two biopsy proven mild rejections and two were not biopsied). These four were treated with methylprednisolone boluses and then withdrawal of steroids again. Prednisone was restarted in five patients because of generalized fatigue and body aches (n = 4) and colitis (n = 1). Steroids later were successfully withdrawn in two of these patients. After prednisone withdrawal, three of five insulin- dependent diabetic patients were able to discontinue insulin therapy and their glycosylated hemoglobin levels improved. Four of fourteen hypertensive patients were able to discontinue antihypertensive medicines. Mean serum cholesterol decreased from 222.6 ± 43.3 to 188.3 ± 33.3 mg/dL (P < .001). The number of patients with serum cholesterol levels > 220 mg/dL decreased from 13 to 4. A control group of 24 patients maintained on 5 mg/d prednisone at least 2 years after liver transplantation also was studied. In this group during the study period, no diabetic became normoglycemic, no patient decreased their anti-hypertensive medicine, and the mean serum cholesterol levels did not change significantly. We conclude that prednisone withdrawal using cyclosporine monotherapy late after liver transplantation does not lead to graft loss and decreases the prevalence of diabetes, hypertension, and hypercholesterolemia. Symptoms occurring during withdrawal may be minimized by earlier or slower tapering.

AB - We prospectively withdrew prednisone in 28 adult patients who had stable graft function more than 2 years after orthotopic liver transplantation (OLTx) and had been on 5 mg/d prednisone for at least 6 months. Prednisone was decreased from 5 mg/d to 2.5 mg/d for 1 month then stopped completely. Cyclosporine monotherapy was maintained at a level of approximately 200 ng/mL (TDX). Nineteen patients had prednisone withdrawn without complications. Four (14.2%) had modest elevations in liver function tests (two biopsy proven mild rejections and two were not biopsied). These four were treated with methylprednisolone boluses and then withdrawal of steroids again. Prednisone was restarted in five patients because of generalized fatigue and body aches (n = 4) and colitis (n = 1). Steroids later were successfully withdrawn in two of these patients. After prednisone withdrawal, three of five insulin- dependent diabetic patients were able to discontinue insulin therapy and their glycosylated hemoglobin levels improved. Four of fourteen hypertensive patients were able to discontinue antihypertensive medicines. Mean serum cholesterol decreased from 222.6 ± 43.3 to 188.3 ± 33.3 mg/dL (P < .001). The number of patients with serum cholesterol levels > 220 mg/dL decreased from 13 to 4. A control group of 24 patients maintained on 5 mg/d prednisone at least 2 years after liver transplantation also was studied. In this group during the study period, no diabetic became normoglycemic, no patient decreased their anti-hypertensive medicine, and the mean serum cholesterol levels did not change significantly. We conclude that prednisone withdrawal using cyclosporine monotherapy late after liver transplantation does not lead to graft loss and decreases the prevalence of diabetes, hypertension, and hypercholesterolemia. Symptoms occurring during withdrawal may be minimized by earlier or slower tapering.

UR - http://www.scopus.com/inward/record.url?scp=0031032623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031032623&partnerID=8YFLogxK

M3 - Article

C2 - 8985286

AN - SCOPUS:0031032623

VL - 25

SP - 173

EP - 177

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -